Steven Stein, M.D. joined Incyte in 2015 and currently serves as the Company’s Executive Vice President and Chief Medical Officer. In his role as CMO, he oversees verticals including clinical development, clinical operations, pharmacovigilance, statistics and data management and regulatory affairs. Prior to joining Incyte, he worked at Novartis Pharmaceuticals Corporation, most recently as Senior Vice President, U.S. Clinical Development & Medical Affairs for Novartis Oncology. Prior to his tenure at Novartis, Dr. Stein worked at GSK (formerly GlaxoSmithKline) as Vice President, Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein was previously an Assistant Professor in the Department of Medicine at the University of Pennsylvania, where he had also completed a fellowship in Hematology and Oncology. Dr. Stein earned his medical degree from the University of Witwatersrand in Johannesburg, South Africa.

Paula Swain joined Incyte in 2002 and serves as the Company’s Executive Vice President of Global Human Resources & Facilities. Additionally, Ms. Swain chairs the Incyte Charitable Giving Foundation.  Before joining the company, Ms. Swain spent nearly 10 years with DuPont (acquired by Bristol Myers Squibb Company in 2001), where she served as Vice President and Senior Vice President of Global Human Resources. She has also held positions in human resource planning and employee relations with Chase Manhattan Bank, Marine Midland Bank and Delaware Trust Company. Ms. Swain received her Bachelor of Arts in Psychology from Rockhurst University and graduated from the Strategic Human Resources Planning program at Harvard Business School.

Bill Meury joined Incyte in 2025 as President, Chief Executive Officer (CEO) and a member of the Company’s Board of Directors. With over three decades of industry experience, Mr. Meury is a proven enterprise leader with expertise in organizational strategy, pipeline and commercial execution and capital allocation.

Prior to joining Incyte, Mr. Meury was CEO of Anthos, where he successfully scaled the company for its next stage of growth. Before joining Anthos Therapeutics, Mr. Meury served as President and CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Prior to Karuna, he served as a Partner at Hildred Capital Management, a private equity firm focusing on healthcare products and services.

Earlier in his career, Mr. Meury spent more than two decades at Allergan, serving as Chief Commercial Officer, managing a global business with fifty products, $16 billion in revenue and approximately 8,000 employees across a range of therapeutic areas. He also served as Allergan’s President, Branded Pharma and Executive Vice President, Commercial, North American Brands, and as Executive Vice President Commercial Operations at Forest Laboratories prior to its acquisition by Allergan.

Mr. Meury has experience across a broad range of therapeutics areas and has been involved with over 20 U.S. FDA approvals and new product launches, as well as 25 different BD&L transactions.

He received his Bachelor of Arts degree in Economics from the University of Maryland and currently serves on the board of The Jed Foundation.